CRSP
CRISPR Therapeutics AG
CRSP
CRISPR Therapeutics AG
CRISPR Therapeutics NASDAQ: CRSP CEO Sam Kulkarni outlined the company's commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected
CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead approved asset and multiple upcoming catalysts. CRSP's valuation reflects a 38% drawdown from its 52-week high,
CRISPR Therapeutics confirmed a dual breakout from inverse head and shoulders patterns, strengthening the bullish outlook and pointing to additional upside if resistance continues to give way.
Crispr Therapeutics secured FDA pediatric approval for Casgevy, expanding its addressable market and reinforcing its leadership in CRISPR/Cas9 gene editing. Casgevy's robust clinical efficacy, global